Ignite Creation Date:
2024-05-06 @ 3:16 AM
Last Modification Date:
2024-10-26 @ 11:30 AM
Study NCT ID:
NCT02245477
Status:
UNKNOWN
Last Update Posted:
2021-02-02
First Post:
2014-09-17
Brief Title:
Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction
Sponsor:
Beni-Suef University
Organization:
Beni-Suef University
Study Overview
Official Title:
Evaluation of Maternal Serum VEGF in Pregnant Women With Foetal Growth Restriction
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VEGF in FGR
Brief Summary:
In this study we explore To explore the role of maternal serum vascular endothelial growth factor VEGF in pregnancies complicated by foetal growth restriction
Detailed Description:
Small-for-gestational age SGA is defined as an estimated foetal weight EFW or abdominal circumference AC less than the 10th centileand severe SGA as an EFW or AC less than the 3rd centile Foetal Growth Restriction refers to failure of the foetus to achieve its predetermined growth potential for various reasonsFoetus with foetal growth restriction FGR greatly contributes to perinatal mortality and short- and long-term morbidity There is a 3-10 fold increase in perinatal mortality in pregnancies complicated by this FGR The incidence of FGR in newborns ranges between 3 and 7 of the total population FGR is thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels leading to placental hypoperfusion and thus fetal undernutrition However the effects of hypoxia on the fetoplacental vessels have been surprisingly little studiedVascular endothelial growth factor VEGF is one of the factors that take part in placental angiogenesis It is highly expressed during embryonic and foetal developmentAngiogenesis involves the branching of new microvessles from pre-existing larger blood vesselsAngiogenesis plays a role in the development of the villous vasculature and the formation of terminal villi in human placenta IUGR occurs as a result of the failure of elongation branching and dilatation of the capillary loops and of terminal villous formation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None